Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company specializing in innovative therapies for back-of-the-eye diseases. Their flagship product, XIPERE, is a treatment for uveitis macular edema. Additionally, the company is developing CLS-AX, an axitinib injectable suspension, and CLS-301, an integrin inhibitor suspension, for diabetic macular edema and macular degeneration. Clearside Biomedical generates revenue through the sale of XIPERE and potential future sales of CLS-AX and CLS-301, as well as through collaborations with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences.

Products

• XIPERE - triamcinolone acetonide suprachoroidal injectable suspension

• CLS-AX - axitinib injectable suspension

• CLS-301 - integrin inhibitor suspension